Heparin mimetics as potential intervention for COVID-19 and their bio-manufacturing

Area of Science:

• Biochemistry
• Virology
• Pharmacology

Background:

• The COVID-19 pandemic presents a significant global health and economic challenge, necessitating novel antiviral strategies.
• Heparin and its derivatives have demonstrated therapeutic benefits, particularly in thrombosis treatment.
• Heparan sulfate plays a crucial role in SARS-CoV-2 infection, and heparin exhibits inhibitory effects.

Purpose of the Study:

• To review the anticoagulant properties of heparin and its potential pharmaceutical applications in treating viral infections, specifically COVID-19.
• To explore the development of heparin mimetics as potential anti-SARS-CoV-2 drug candidates.
• To summarize methods for producing heparin mimetics, including chemical synthesis, chemoenzymatic synthesis, and microbial bioengineering.

Main Methods:

• Review of existing clinical data on low molecular weight heparin (LMWH) in COVID-19 patients.
• Analysis of in vitro studies investigating the role of heparan sulfate in SARS-CoV-2 infection.
• Examination of different synthetic and bioengineered approaches for developing heparin mimetics.

Main Results:

• LMWH treatment in COVID-19 patients was associated with decreased inflammatory cytokine levels and reduced mortality.
• In vitro studies confirm heparan sulfate's involvement in SARS-CoV-2 infection and heparin's inhibitory potential.
• Heparin mimetics present a viable strategy for developing novel antiviral therapies.

Conclusions:

• Heparin and its mimetics hold significant potential as therapeutic agents against SARS-CoV-2.
• Developing heparin mimetics through various synthesis and production methods is a promising avenue for novel antiviral drug discovery.
• Further research into heparin mimetics is crucial for addressing the ongoing need for effective treatments for coronavirus infections.